This is based on an assumption that tuberous sclerosis (TS) is the most frequent syndromic presentation of cardiac tumors, and mTOR inhibitors are effective in treating CNS and kidney neoplasms of TS (Curatolo and Moavero 2012). The gene discussed is MTOR; the disease is tuberous sclerosis.